


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+1.99%
+2.67%
+4.23%
+0.07%
+3.45%
META
Meta Platforms
$639.30
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Outperform the market
META Price Performance
$672.97 (-5.00%)
$633.61 (+0.90%)
$734.38 (-12.95%)
$605.71 (+5.55%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings increase YoY
Revenue increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
META Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
META Street Sentiment is extremely bullish and have positive views on the near-term outlook
META has Low risk level
Risk Indicators
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Feb 05, 2026
Price Target Raised
Buy
Freedom Capital
Jan 30, 2026
Reiterate
Buy
Stifel
Jan 26, 2026
Upgrade
Buy
Roth
Jan 21, 2026
Price Target Raised
Buy
BofA
Jan 21, 2026
Reiterate
Buy
Truist Securities
GOOG
Alphabet
310.92
-0.25%
PINS
16.95
+1.50%
WB
10.31
+0.39%
TRIP
TripAdvisor
10.06
0.00%
BIDU
Baidu
133.63
-0.23%
What is META current stock price?
What are META stock strengths?
What is META Risk Level?
What is META market cap and volume?
What is META current Stock IQ?
Should I buy META stock right now?
Is META a Strong Buy right now?
What does a 'Strong Buy' rating mean for META?
What does a 'Strong Sell' rating mean for META?
What factors influence META's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
META
Meta Platforms
Current Price
$639.30
Runners Also Watch
GOOG
Alphabet
310.92
-0.25%
PINS
16.95
+1.50%
WB
10.31
+0.39%
TRIP
TripAdvisor
10.06
0.00%
BIDU
Baidu
133.63
-0.23%

META Price Performance
$672.97 (-5.00%)
$633.61 (+0.90%)
$734.38 (-12.95%)
$605.71 (+5.55%)
META Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings increase YoY
Revenue increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
META Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
META Street Sentiment is extremely bullish and have positive views on the near-term outlook
META has Low risk level
Risk Indicators
Average key support and resistance price levels
Overall Wall Street Rating
META Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Outperform the market
META Latest Analysis
Agenus (AGEN) Presents New Phase 1b Clinical Data on BOT/BAL Combination for MSS mCRC. Agenus Inc. (NASDAQ:AGEN) is one of the most undervalued penny stocks to buy right now. On February 19 Agenus presented new translational and clinical biomarker data from its Phase 1b C-800-01 trial focusing on the combination of botensilimab/BOT and balstilimab/BAL. The study highlighted the therapys effectiveness in immunologically cold tumors such as microsatellite-stable metastatic colorectal [….]
Today
AMD Meta Expand Partnership To Deploy Up To 6 Gigawatts Of AI GPUs . (RTTNews) - Advanced Micro Devices Inc. (AMD) and Meta Platforms Inc. (META) have reached a multi-year strategic partnership to deploy up to 6 gigawatts of AMD Instinct GPUs to support Metas next-generation artificial intelligence infrastructure.
Today
Meta Announces Major Chips-for-Stock Deal With AMD. Lisa Su AMDs chief executive has been trying to break into a market for A.I. chips that has been dominated by Nvidia.
Today
Aktis Oncologys AKY-1189 Wins FDA Fast Track Designation . (RTTNews) - Aktis Oncology Inc. (AKTS) Tuesday announced that the United States Food and Drug Administration has granted Fast Track designation to AKY-1189 for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
Today
Meta strikes AI chip deal with AMD days after committing to deploy millions of Nvidia GPUs. AMD has secured Meta as a customer for its Helios rack-scale system as Nvidias Blackwell faces heightened competition.
Today
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer. 177Lu) vipivotide tetraxetan) effectiveness and sequencing as well as real‑world treatment patterns in earlier metastatic disease. These studies will be presented at the ASCO Genitourinary Cancers Symposium on February 26 2026.
Today
AMD clinches second mega chip supply deal this time with Meta.
Today
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
META Stock trends
META Stock performance
META Stock analysis
META investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.